X0306 4 2017-02-06 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001423838 Grigoriadis Dimitri E. 12780 EL CAMINO REAL SAN DIEGO CA 92130 0 1 0 0 Chief Research Officer Common Stock 2017-02-06 4 S 0 727 43.13 D 115756 D Stock Option 43.24 2017-02-06 4 A 0 51600 0.00 A 2027-02-06 Common Stock 51600 51600 D Restricted Stock Option 2017-02-06 4 A 0 6100 0.00 A Common Stock 6100 6100 D Sale of 727 shares of common stock issued upon vesting of 1925 restricted stock units to cover withholding taxes with the balance of the shares (1198) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $42.69 to $43.41. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2017 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021. /s/ Darin Lippoldt, Attorney-In-Fact 2017-02-08